
Sandoz Group Investor Relations Material
Latest events

Q2 2025
Sandoz Group
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Sandoz Group AG
Access all reports
Sandoz Group AG is a swiss pharmaceutical company focusing on the development, manufacture, and marketing of generic pharmaceuticals and biosimilars.Sandoz operates in two primary segments: generics, which include drugs that are structurally equivalent to original drugs whose patents have expired, and biosimilars, which, unlike generics, are slightly different from other approved reference biologics but have no clinically significant differences. With a global footprint, Sandoz engages in the healthcare technology field by buying and selling intellectual property and other assets related to generics and biosimilar drugs, both domestically and internationally. The company is headquartered in Rotkreuz, Switzerland, and its shares are listed on the SIX Swiss Exchange.
Key slides for Sandoz Group AG


Investor Presentation
Sandoz Group AG


Q2 2025
Sandoz Group AG
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
SDZ
Country
🇨🇭 Switzerland